Cash infusion fast tracks InhaleRx inhaled therapies
Biotechnology company InhaleRx has secured $38.5 million in funding to further develop its precision medicines delivered via inhalation. Clendon Biotech Capital has entered into a strategic partnership with the company to provide funding to cover all direct costs associated with the Phase 1 & 2 clinical development of its’ key drug development projects – IRX-211…